Position in ZYME
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,417,331
-$524,414 QoQ
Shares Held
176,411
-6.0% QoQ
Ownership
0.242%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 46%
Shared 0%
None 54%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RAYMOND JAMES FINANCIAL INC holds $1,498,619,160 across 194 Biotechnology names. ZYME ranks #46 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
444,496 | $198,485,243 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
406,956 | $134,649,528 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
165,542 | $127,904,369 | |
| 4 | INSM |
INSMED Inc
|
775,148 | $126,752,197 | |
| 5 | RPRX |
Royalty Pharma plc
|
1,524,018 | $73,107,140 | |
| 6 | VKTX |
Viking Therapeutics, Inc.
|
2,075,403 | $67,533,612 | |
| 7 | EXEL |
Exelixis, Inc.
|
1,045,595 | $44,845,567 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
156,064 | $40,314,451 |
All Filings in ZYME
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,417,331 | 176,411 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $4,941,745 | 187,685 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $2,098,584 | 122,868 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $1,561,658 | 124,435 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $1,390,026 | 116,711 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $887,798 | 60,642 | Shares | Defined | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||